These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Scl-86, a marker antigen for diffuse scleroderma. van Venrooij WJ; Stapel SO; Houben H; Habets WJ; Kallenberg CG; Penner E; van de Putte LB J Clin Invest; 1985 Mar; 75(3):1053-60. PubMed ID: 3980727 [TBL] [Abstract][Full Text] [Related]
6. Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports. Al Attia HM; D'Souza MS Clin Rheumatol; 2003 Feb; 22(1):70-2. PubMed ID: 12605324 [TBL] [Abstract][Full Text] [Related]
7. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Habets WJ; de Rooij DJ; Salden MH; Verhagen AP; van Eekelen CA; van de Putte LB; van Venrooij WJ Clin Exp Immunol; 1983 Oct; 54(1):265-76. PubMed ID: 6352106 [TBL] [Abstract][Full Text] [Related]
8. [The Scl-70 antibody and its clinical significance]. Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S Dermatol Monatsschr; 1989; 175(3):133-47. PubMed ID: 2653887 [TBL] [Abstract][Full Text] [Related]
9. Determination of anti-Scl-70 antibody and its clinical significance in progressive systemic sclerosis. Jiang M; Song QF; Wang SZ; Yuan X; Zhang NZ Proc Chin Acad Med Sci Peking Union Med Coll; 1986; 1(4):247-9. PubMed ID: 3124097 [No Abstract] [Full Text] [Related]
10. [The fibrillarin (Scl-34) autoantibody in systemic scleroderma]. Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Chorzelski TP; Jablonska S Dermatol Monatsschr; 1990; 176(1):19-26. PubMed ID: 2178987 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens. Damoiseaux J; Boesten K; Giesen J; Austen J; Tervaert JW Ann N Y Acad Sci; 2005 Jun; 1050():340-7. PubMed ID: 16014550 [TBL] [Abstract][Full Text] [Related]
13. [Demonstration of antinuclear antibodies in the epidermis of patients with progressive systemic sclerosis, generalized lupus erythematosus and dermatomyositis]. Lamas Robles C; Mejía Arreguín S; Orozco Medina JH; González Mendoza A Rev Invest Clin; 1984; 36(2):115-9. PubMed ID: 6385174 [No Abstract] [Full Text] [Related]
14. [Significance of antinuclear antibodies in overlap syndromes. I. Relationship between systemic lupus erythematosus, diffuse scleroderma and dermatomyositis]. Zitnan D; Rovenský J; Cebecauer L; Hajzok O Fysiatr Revmatol Vestn; 1973 Jun; 51(3):152-7. PubMed ID: 4592583 [No Abstract] [Full Text] [Related]
15. [Detection of antibodies to extractable nuclear antigens with counterimmunoelectrophoresis and the Western blot technic]. Hauke G; Lührmann R; Metz B; Peter HH Z Rheumatol; 1988; 47(1):26-9. PubMed ID: 3259356 [TBL] [Abstract][Full Text] [Related]
16. Anti-NuMA antibodies: an uncommon specificity in scleroderma sera. Herrera-Esparza R; Avalos-Diaz E; Barbosa-Cisneros O Rev Rhum Engl Ed; 1999 Jun; 66(6):315-8. PubMed ID: 10418059 [TBL] [Abstract][Full Text] [Related]